(Mark One)
|
||
|
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
|
For the fiscal year ended
|
|
or
|
||
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
||
|
|
|
|
☒
|
Accelerated filer
|
☐
|
Non-accelerated filer
|
☐
|
Smaller reporting company
|
|
Emerging growth company
|
|
Name
|
Age
|
Director since
|
Independent
|
Position
|
Francesco Bianchi
|
63
|
2015
|
Yes
|
Chairman, Seven Capital Partners S.r.l.
|
Stacy Enxing Seng
|
55
|
2019
|
Yes
|
Venture Partner, Lightstone Ventures
|
William Kozy
|
68
|
2018
|
Yes
|
Retired, EVP and COO, Becton, Dickinson and Company
|
Damien McDonald
|
55
|
2017
|
No
|
Chief Executive Officer, LivaNova
|
Daniel Moore
|
59
|
2015
|
Yes
|
Chairman of the Board, Private Investor
|
Hugh Morrison
|
73
|
2015
|
Yes
|
Independent Consultant and Private Investor
|
Alfred Novak
|
72
|
2015
|
Yes
|
Private Investor
|
Sharon O'Kane
|
52
|
2015
|
Yes
|
Entrepreneur in Residence, University College Dublin
|
Arthur Rosenthal
|
73
|
2015
|
Yes
|
Retired CEO, EyeCue, Inc.
|
Andrea Saia
|
62
|
2016
|
Yes
|
Retired, Global Head of Vision Care, Alcon Division, Novartis AG
|
Name
|
Age
|
Position
|
Damien McDonald
|
55
|
Chief Executive Officer
|
Thad Huston
|
50
|
Chief Financial Officer
|
Keyna Skeffington
|
58
|
Senior Vice President, General Counsel and Corporate Secretary
|
Edward Andrle
|
62
|
Former General Manager, Neuromodulation Franchise
|
Alistair Simpson
|
50
|
Former General Manager, Cardiovascular Franchise
|
Marco Dolci
|
58
|
Head of Global Operations and R&D
|
Trui Hebbelinck
|
48
|
Chief Human Resources Officer
|
Roy Khoury
|
46
|
President, International, Senior Vice President, Global Strategic Marketing
|
•
|
reviewing our consolidated financial statements and internal controls with management and the independent auditors;
|
•
|
monitoring actions we take to comply with our internal accounting and control policies as well as external financial, legal and regulatory requirements;
|
•
|
monitoring our internal audit functions;
|
•
|
reviewing the qualifications and independence of our independent auditors engaged for the purpose of auditing our consolidated financial statements and issuing an audit report for inclusion in appropriate regulatory filings; and
|
•
|
selecting, subject to required shareholder approvals, our independent auditors and evaluating their performance.
|
•
|
reviewed and discussed with management and the independent registered public accounting firm our consolidated financial statements for the year ended December 31, 2019 and the quarters ended March 31, 2019, June 30, 2019 and September 30, 2019;
|
•
|
oversaw and discussed with management the review of internal control over our financial reporting;
|
•
|
reviewed management’s representations that our consolidated financial statements were prepared in accordance with GAAP and present fairly our results of operations and financial position;
|
•
|
discussed with the independent registered public accounting firm the matters required to be discussed by Auditing Standard No. 1301, Communications with Audit Committee;
|
•
|
received the written disclosures and letter from the independent registered public accounting firm required by the applicable requirements of the Public Company Accounting Oversight Board regarding the independent registered public accounting firm’s communication with the Audit and Compliance Committee concerning independence, and discussed with the independent registered public accounting firm its independence;
|
•
|
reviewed and evaluated the performance and quality of the independent registered public accounting firm and its lead audit partner in its determination to recommend the retention of the independent registered public accounting firm, including by assessing the performance of the independent registered public accounting firm from within the Audit and Compliance Committee and from the perspective of senior management and the internal auditor;
|
•
|
considered whether the provision of non-audit services by our registered public accounting firm is compatible with maintaining the registered public accounting firm’s independence;
|
•
|
reviewed the scope of and overall plans for the annual audit and the internal audit program;
|
•
|
reviewed new accounting standards applicable with our CFO, internal audit department and our external auditors;
|
•
|
consulted with management with respect to our processes for risk assessment and risk mitigation;
|
•
|
reviewed our processes for monitoring compliance with the law and Company policies and Code of Business Conduct and Ethics; and
|
•
|
reviewed and discussed with management its assessment and report on the effectiveness of our internal control over financial reporting as of December 31, 2019.
|
•
|
Damien McDonald, CEO;
|
•
|
Thad Huston, CFO;
|
•
|
Keyna Skeffington, SVP, GC and Corporate Secretary;
|
•
|
Edward Andrle, Former GM, Neuromodulation Franchise; and
|
•
|
Alistair Simpson, Former GM, Cardiovascular Franchise.
|
•
|
The Company’s total net sales were $1,084.2 million versus $1,107.0 in 2018, a decrease of 2.1% from 2018;
|
•
|
Cardiovascular sales were $656.6 million, a 0.7% decrease from 2018;
|
*
|
Sales in cardiopulmonary products were $504.7 million, a 3.1% decrease from 2018, primarily due to the impact of exiting a Canadian distribution agreement and a component supplier issue related to the Inspire oxygenator;
|
*
|
Heart valve sales, including tissue and mechanical heart valves, were $120.0 million, a decrease of 0.7% compared to 2018; and
|
*
|
Advanced Circulatory Support (“ACS”) sales were $31.9 million, an increase of 64.1%, primarily related to growth in ProtekDuo and one additional quarter of sales in 2019 versus 2018 since the acquisition of TandemLife in April 2018;
|
•
|
Neuromodulation sales were $424.5 million, a 1.2% increase compared to 2018, primarily driven by adoption of the SenTiva VNS Therapy System and very strong growth in the Europe and Rest of World regions; and
|
•
|
The full year operating loss from continuing operations was $168.9 million and adjusted operating income from continuing operations was $179.7 million, a decrease of 16.9% as compared to 2018, primarily impacted by performance in Neuromodulation, investments in research and development to support Strategic Portfolio Initiatives,
|
•
|
In February 2019, the US Centers for Medicare & Medicaid Services (“CMS”) finalized its National Coverage Determination for the Vagus Nerve Stimulation (“VNS”) Therapy System for difficult to treat depression ("DTD") which initiates coverage for Medicare beneficiaries through Coverage with Evidence Development when offered in a CMS-approved, double-blind, randomized placebo-controlled trial with a follow-up duration of one year, as well as coverage for VNS Therapy device replacement.
|
•
|
In July 2019, we launched Bi-Flow, our innovative arterial femoral cannula, which received CE Mark in early 2019 and is the only bidirectional arterial cannula designed to prevent leg ischemia during cardiac surgery procedures requiring femoral artery cannulation.
|
•
|
In July 2019, we acquired Miami Instruments, LLC’s minimally invasive cardiac surgery instruments business for cash consideration of up to $17.0 million.
|
•
|
In July 2019, the US Food and Drug Administration approved our LifeSPARC system, a new generation of the ACS pump and controller and we began a limited commercial release in the US.
|
•
|
In September 2019, CMS accepted the protocol for our RECOVER clinical study, evaluating VNS Therapy for DTD. RECOVER is a double-blind randomized, placebo-controlled study with a follow-up duration of at least one year. RECOVER will include up to 500 unipolar and up to 500 bipolar patents at a maximum of 100 sites in the US.
|
•
|
Target NEO pay around the market median to attract, motivate and retain talented executive officers with the skills and experience to ensure our long-term success;
|
•
|
Use multiple pay and award vehicles that work together to reward performance and retain talent, while maintaining alignment with shareholder interests;
|
•
|
Reward individual performance with base salary and a cash-based short-term bonus while ensuring a meaningful link to our operational performance and shareholder interests;
|
•
|
Pay a substantial portion of each NEO’s compensation as variable pay contingent upon the achievement of our business objectives;
|
•
|
Balance the components of compensation so that short-term (annual) and long-term performance objectives are recognized because our success depends on our executive officers being focused on critical strategic and tactical objectives, both short-term and long-term;
|
•
|
Encourage NEOs to have a meaningful ownership interest in the Company with stock ownership guidelines;
|
•
|
Vest equity awards over time to promote retention and mitigate risks;
|
•
|
Have clawback provisions in our plans to mitigate risks; and
|
•
|
Work with an independent compensation consultant to ensure our program is meeting its goals.
|
•
|
Having a double trigger change in control provision before cash severance may be paid;
|
•
|
Prohibiting excise tax gross-up payments;
|
•
|
Prohibiting stock option repricing and discounted stock option grants;
|
•
|
Not allowing our officers or directors to pledge their LivaNova stock, subject to a transition period to unwind any existing obligations;
|
•
|
Prohibiting hedging transactions of any type of Company security, including without limitation puts, calls, equity swaps, collars, exchange funds, prepaid variable forwards or other financial instruments or derivative securities; and
|
•
|
Allocating 50% of NEO long-term incentives to performance-based awards.
|
•
|
recommends performance objectives for our annual STIP;
|
•
|
recommends adjustments to annual base salaries and target amounts under our STIP;
|
•
|
recommends equity incentive awards under our long-term incentive plan (“LTIP”);
|
•
|
prepares an evaluation of each executive officer; and
|
•
|
prepares an analysis of performance objective achievements and recommends annual bonus amounts.
|
•
|
Assessment of Company Performance.
The Compensation Committee establishes specific, measurable company performance objectives that the Board, the Compensation Committee and management believe will drive shareholder value. Achievement or failure to achieve those performance objectives determines substantially all of
|
•
|
Assessment of Individual Performance.
Individual performance has a strong impact on compensation.
|
*
|
CEO
. The Compensation Committee meets with our CEO at the beginning of the year to agree on the CEO’s performance objectives for the year. At the end of the year, the Compensation Committee and the chairman of the Board meet in executive session to assess the CEO’s performance against his performance objectives, his contribution to our performance, his ethics and integrity and other leadership attributes
.
|
*
|
Other NEOs
. For all other NEOs, the Compensation Committee receives performance assessments and compensation recommendations from the CEO and also exercises its judgment based on the Board’s interactions with the individuals. As with the CEO, an executive officer’s performance assessment is based on individual achievements and contributions, contribution to our company’s performance, ethics and integrity and other leadership accomplishments
.
|
•
|
Benchmarking Analysis.
The Compensation Committee reviews peer-group data as a market check for compensation decisions, but does not base compensation targets on peer-group data alone. The Compensation Committee compares the overall pay of individual NEOs to the most relevant benchmarking data available from its independent advisor, Pearl Meyer. The NEO’s pay is driven primarily by individual and Company performance, as well as internal pay equity; peer group data is used as a market check to compare individual pay to the broad middle range (25th to 75th percentile) of peer group pay. The Compensation Committee typically seeks to maintain base salary toward the middle of peer group pay, but will permit annual bonus opportunities and long-term equity incentive awards to approach the upper end of the broad middle range when justified by individual and Company performance. Pearl Meyer uses the peer group companies as well as survey data from Radford to perform the benchmark analysis.
|
Abiomed, Inc.
|
Masimo Corporation
|
Cantel Medical Corp.
|
Merit Medical Systems, Inc.
|
CONMED Corporation
|
Nuvasive, Inc.
|
DexCom, Inc.
|
ResMed Inc.
|
Globus Medical, Inc.
|
STERIS plc
|
Hill-Rom Holdings, Inc.
|
Teleflex Incorporated
|
Hologic, Inc.
|
The Cooper Companies, Inc.
|
ICU Medical, Inc.
|
Varian Medical Systems, Inc.
|
Integer Holdings, Corporation
|
West Pharmaceutical Services, Inc.
|
Integra LifeSciences Holdings Corporation
|
Wright Medical Group, N.V.
|
•
|
Overall Competitiveness
. The Compensation Committee uses aggregated market data from the Radford survey data as well as the peer group as a reference point to ensure that executive compensation falls within the broad middle range of comparable pay at peer companies with which the Company competes for talent.
|
•
|
UK Remuneration Policy
.
For our CEO, who is also a director, the Compensation Committee must ensure that any compensation plan it approves for him is consistent with our shareholder-approved UK remuneration policy. Under English company law, we were obliged to adopt a remuneration policy for our directors, including our CEO, who is also a director. Under that shareholder-approved remuneration policy, our CEO's maximum short-term incentive opportunity cannot exceed 200% of his base salary. In the case of a calculated payment higher than 200%, the Compensation Committee would affirmatively act to reduce the award to not exceed 200% of his base salary in compliance with the UK remuneration policy.
|
Element and Purpose
|
Key Features
|
Base Salary
Purpose: Attract and retain NEOs; compensate for individual performance
|
Fixed annually at the beginning of the financial year by the Compensation Committee
Measured against compensation peer group
Serves as the baseline from which short-term incentives are calculated
|
Short-Term Incentives
Purpose: Provide formulaic incentives to achieve or exceed budgeted Adjusted Net Sales (1) and Adjusted Net Income (2) and drive non-financial initiatives supporting our success
|
Annual cash-based bonus plan expressed as a percentage of the NEO’s weighted average base salary
Incentive payouts range from threshold to maximum levels, depending on level of performance measured against Compensation Committee determined metrics
Bonus payment based on the achievement of two financial objectives - budgeted Adjusted Net Sales and Adjusted Net Income - eight non-financial objectives relating to: design, clinical, regulatory and commercialization projects; and, with the exception of Mr. McDonald, leadership
|
Long-Term Incentives
Purpose: Create alignment with shareholder interests; motivate, attract and retain top talent
|
Service-Based Awards
:
Restricted Stock Units vest in equal or substantially equal amounts on each of the first four anniversaries of the grant date
Stock Appreciation Rights vest in equal or substantially equal amounts on each of the first four anniversaries of the grant date
Performance-Based Awards
:
Relative Total Shareholder Return Performance Stock Units are subject to a three-year relative total shareholder return market condition
Adjusted Free Cash Flow Performance Stock Units are subject to achievement of a three-year cumulative adjusted free cash flow target
|
(1)
|
Adjusted Net Sales are our net sales at budgeted currency exchange rates, excluding net sales from acquisitions.
|
(2)
|
Adjusted Net Income is our non-GAAP net income at reported currency exchange rates, after adjustments for the effects of acquisitions, divestitures, restructuring, integration, purchase price allocation and intangible amortization, special items, including 3T Heater Cooler remediation and significant and unusual litigation, including 3T Heater Cooler litigation, and equity compensation.
|
•
|
Approved the 2019 STIP and the 2019 LTIP;
|
•
|
Re-appointed Pearl Meyer as its compensation advisor for the 2019 financial year;
|
•
|
Approved base salaries and STIP percentages for all NEOs; and
|
•
|
Amended the Employee Stock Purchase Plan to eliminate open market purchases.
|
U.S. Target Total Cash Benchmark Percentile
|
|
Damien McDonald
|
69th
|
Thad Huston
|
>75th
|
Keyna Skeffington
|
51st
|
•
|
Individual performance during the recently concluded financial year and potential future contribution;
|
•
|
Responsibilities, including any recent changes in those responsibilities;
|
•
|
Level of expertise and experience of the NEO compared to that required for a position;
|
•
|
Strategic importance of a position;
|
•
|
Internal pay equity among positions; and
|
•
|
Competitive benchmarking data.
|
2019 Base Salary ($)
|
2018 Base Salary ($)
|
Change from 2018 (1)
|
|
Damien McDonald
|
933,202
|
933,202
|
0%
|
Thad Huston
|
516,674
|
492,754
|
5%
|
Keyna Skeffington
|
433,751
|
395,479
|
10%
|
Edward Andrle
|
440,000
|
400,000
|
10%
|
Alistair Simpson
|
433,751
|
395,479
|
10%
|
(1)
|
For salary amounts, we used an exchange rate of $1.275738014 per British Pound, each of which reflects the applicable period average published rate from our BOPC Accounting System between January 1, 2019 and December 31, 2019. The BOPC Accounting System uses Bloomberg as a source to obtain exchange rates.
|
U.S. Target Total Cash Benchmark Percentile
|
|
Damien McDonald
|
69th
|
Thad Huston
|
>75th
|
Keyna Skeffington
|
51st
|
Name
|
2019 STIP Minimum (Percentage of Base Salary)
|
2019 STIP Target (Percentage of Base Salary)(1)
|
2019 STIP Maximum (Percentage of Target)
|
|||
Damien McDonald
|
0
|
%
|
125
|
%
|
171
|
%
|
Thad Huston
|
0
|
%
|
90
|
%
|
160
|
%
|
Keyna Skeffington
|
0
|
%
|
70
|
%
|
160
|
%
|
Edward Andrle
|
0
|
%
|
65
|
%
|
156
|
%
|
Alistair Simpson
|
0
|
%
|
60
|
%
|
156
|
%
|
(1)
|
The Target Percentages for the following NEOs changed in 2019 as follows: Damien McDonald: 100% from January through March and increased to 125% effective April 1, 2019; Keyna Skeffington: 60% from January through March 31, 2019 and increased to 70% effective April 1, 2019; Ed Andrle: 60% from January through March 31, 2019 and increased to 65% effective April 1, 2019; and Alistair Simpson: 50% from January through March 31, 2019 and increased to 60% effective April 1, 2019.
|
Non-Financial Objectives
|
|||||
Design
|
Clinical
|
Regulatory
|
Commercialization
|
Leadership
|
|
Damien McDonald
|
10%
|
10%
|
15%
|
5%
|
N/A
|
Thad Huston
|
10%
|
10%
|
15%
|
5%
|
15%
|
Keyna Skeffington
|
10%
|
10%
|
15%
|
5%
|
15%
|
Edward Andrle
|
10%
|
10%
|
15%
|
5%
|
20%
|
Alistair Simpson
|
10%
|
10%
|
15%
|
5%
|
20%
|
STIP Target (% of Base Salary) (1)
|
Financial Performance
Weight %
|
Weighted Financial Performance Payout %
|
Leadership Weight %
|
Leadership
Payout %
|
Weighted Non-Financial Performance
Payout %
|
STIP
Pay-Out %
|
STIP Payout ($)(2)
|
|
Damien McDonald
|
125%
|
75%
|
0%
|
NA
|
N/A
|
25%
|
25%
|
277,245
|
Thad Huston
|
90%
|
60%
|
0%
|
15%
|
12%
|
25%
|
37%
|
170,088
|
Keyna Skeffington
|
70%
|
60%
|
0%
|
15%
|
12%
|
25%
|
37%
|
106,289
|
Edward Andrle
|
65%
|
55%
|
0%
|
20%
|
14%
|
25%
|
39%
|
107,116
|
Alistair. Simpson
|
60%
|
55%
|
7.34%
|
20%
|
14%
|
25%
|
46%
|
113,445
|
(1)
|
The Target Percentages for the following NEOs changed in 2019 as follows: Damien McDonald: 100% from January through March and increased to 125% effective April 1, 2019; Keyna Skeffington: 60% from January through March 31, 2019 and increased to 70% effective April 1, 2019; Ed Andrle: 60% from January through March 31, 2019 and increased to 65% effective April 1, 2019; and Alistair Simpson: 50% from January through March 31, 2019 and increased to 60% effective April 1, 2019.
|
(2)
|
For payout amounts, we used an exchange rate of $1.275738014 per British Pound, each of which reflects the applicable period average published rate from our BOPC Accounting System between January 1, 2019 and December 31, 2019. The BOPC Accounting System uses Bloomberg as a source to obtain exchange rates.
|
|
RSUs ($)
|
SARs ($)
|
rTSR PSUs ($)
|
FCF PSUs ($)
|
Total Award Value ($)
|
Damien McDonald
|
1,250,000
|
1,250,000
|
1,500,000
|
1,500,000
|
5,500,000
|
Thad Huston
|
500,000
|
500,000
|
500,000
|
500,000
|
2,000,000
|
Keyna Skeffington
|
225,000
|
225,000
|
225,000
|
225,000
|
900,000
|
Edward Andrle
|
187,500
|
187,500
|
187,500
|
187,500
|
750,000
|
Alistair Simpson
|
187,500
|
187,500
|
187,500
|
187,500
|
750,000
|
TSR Performance
Percentile Rank
|
Percent Funding for Objective
|
≥90
th
|
200%
|
80
th
|
150%
|
50
th
|
100%
|
30
th
|
40%
|
th
|
0%
|
ABIOMED, Inc.
|
Intuitive Surgical, Inc.
|
Baxter International Inc.
|
Invacare Corporation
|
Becton, Dickinson and Company
|
Masimo Corporation
|
Boston Scientific Corporation
|
Medtronic plc
|
Cantel Medical Corp.
|
Natus Medical Incorporated
|
CONMED Corporation
|
Nevro Corp.
|
DexCom, Inc.
|
Nuvasive, Inc.
|
Edwards Lifesciences Corporation
|
ResMed Inc.
|
Globus Medical, Inc.
|
Smith & Nephew plc
|
Haemonetics Corporation
|
Stryker Corporation
|
Hill-Rom Holdings, Inc.
|
Teleflex Incorporated
|
Hologic, Inc.
|
Varian Medical Systems, Inc.
|
Insulet Corporation
|
Wright Medical Group N.V.
|
Integer Holdings Corporation
|
Zimmer Biomet Holdings, Inc.
|
Integra LifeSciences Holdings Corp.
|
FCF Achievement
Relative to FCF Target (1)
|
Percent Funding for Objective
|
≥150%
|
200%
|
125%
|
150%
|
100%
|
100%
|
60%
|
20%
|
|
0%
|
(1)
|
“Adjusted Free Cash Flow" is defined as the Company’s reported cash flow from operating activities (including ImThera and TandemLife), minus the Company’s reported capital expenditures, and excluding cash flows associated with restructuring, integration, 3-T heater cooler product remediation and significant and unusual litigation and cash paid or received for acquisitions (Caisson, ImThera, TandemLife and future acquisitions), divestitures (CRM and future divestitures) and settlements and judgments in significant and unusual litigation (including 3-T heater-cooler litigation).
|
•
|
medical, dental and vision benefits;
|
•
|
medical and dependent care flexible spending accounts;
|
•
|
short-term and long-term disability insurance; and
|
•
|
group term life insurance.
|
•
|
Approved the 2020 STIP and the 2020 LTIP;
|
•
|
Reappointed Pearl Meyer as compensation advisors for the 2020 financial reporting year;
|
•
|
Approved base salaries and STIP percentages for all NEOs;
|
•
|
Approved the 2020 Peer Group; and
|
•
|
Reduced the 2019 STIP payout to 25% at Target given the Company's overall financial results. The 2019 STIP payout would otherwise have resulted in a 30% achievement at Target.
|
|
2020 Base Salary ($)
|
Increase from 2019
|
2020 STIP at Target
|
Change from 2019
|
Damien McDonald
|
979,862
|
5%
|
125%
|
—
|
Thad Huston
|
532,174
|
3%
|
90%
|
—
|
Keyna Skeffington
|
459,776
|
6%
|
70%
|
—
|
(1)
|
For salary amounts, we used an exchange rate of $1.275738014 per British Pound, each of which reflects the applicable period average published rate from our BOPC Accounting System between January 1, 2019 and December 31, 2019. The BOPC Accounting System uses Bloomberg as a source to obtain exchange rates.
|
2020 STIP Minimum (Percentage of Base Salary)
|
2020 STIP Target (Percentage of Base Salary)
|
2020 STIP Maximum (Percentage of Target)
|
|
Damien McDonald
|
0%
|
125%
|
171%
|
Thad Huston
|
0%
|
90%
|
160%
|
Keyna Skeffington
|
0%
|
70%
|
160%
|
Percent Achievement of Sales Objective
|
Percent Achievement of Income Objective
|
Percent Funding for Objective
|
>110%
|
>110%
|
175%
|
110%
|
110%
|
175%
|
|
Linear Interpolation: 1:7.50
|
|
100%
|
100%
|
100%
|
|
Linear Interpolation: 1:16.67 (Sales)
1.50 (Income)
|
|
97%
|
90%
|
50%
|
|
|
0%
|
|
Design
|
Clinical and Regulatory
|
Commercialization
|
Leadership
|
Damien McDonald
|
10%
|
20%
|
10%
|
NA
|
Thad Huston
|
10%
|
20%
|
10%
|
15%
|
Keyna Skeffington
|
10%
|
20%
|
10%
|
15%
|
RSUs ($)
|
SARs ($)
|
rTSR PSUs ($)
|
FCF PSUs ($)
|
|
Damien McDonald
|
1,500,000
|
1,250,000
|
1,500,000
|
1,500,000
|
Thad Huston
|
500,000
|
500,000
|
500,000
|
500,000
|
Keyna Skeffington
|
250,000
|
250,000
|
250,000
|
250,000
|
TSR Performance
Percentile Rank
|
Percent Funding for Objective
|
≥90
th
|
200%
|
80
th
|
150%
|
50
th
|
100%
|
30
th
|
40%
|
th
|
0%
|
ABIOMED, Inc.
|
Intuitive Surgical, Inc.
|
Baxter International Inc.
|
Invacare Corporation
|
Becton, Dickinson and Company
|
Masimo Corporation
|
Boston Scientific Corporation
|
Medtronic plc
|
Cantel Medical Corp.
|
Natus Medical Incorporated
|
CONMED Corporation
|
Nevro Corp.
|
DexCom, Inc.
|
NuVasive, Inc.
|
Edwards Lifesciences Corporation
|
Penumbra Inc.
|
Globus Medical, Inc.
|
ResMed Inc.
|
Haemonetics Corporation
|
Smith & Nephew plc
|
Hill-Rom Holdings, Inc.
|
Stryker Corporation
|
Hologic, Inc.
|
Teleflex Incorporated
|
Insulet Corporation
|
Varian Medical Systems, Inc.
|
Integer Holdings Corporation
|
Wright Medical Group N.V.
|
Integra LifeSciences Holdings Corp.
|
Zimmer Biomet Holdings, Inc.
|
FCF Achievement
Relative to FCF Target
|
Percent Funding for Objective
|
≥150%
|
200%
|
125%
|
150%
|
100%
|
100%
|
60%
|
20%
|
|
0%
|
Name and Principal Position
|
Year
|
Salary ($)(1)
|
Stock Awards ($)(2)
|
Option Awards ($)(2)
|
Non-Equity Incentive Plan Compensation ($)(1)(3)
|
All Other Compensation ($)(1)(4)
|
Total ($)
|
||||||
Damien McDonald
|
2019
|
933,202
|
|
4,309,277
|
|
1,249,978
|
|
277,244
|
|
362,226
|
|
7,131,927
|
|
Chief Executive Officer
|
2018
|
951,218
|
|
3,522,492
|
|
1,124,847
|
|
999,131
|
|
514,940
|
|
7,112,628
|
|
|
2017
|
847,925
|
|
2,350,821
|
|
—
|
|
848,095
|
|
1,368,920
|
|
5,415,761
|
|
Thad Huston
|
2019
|
510,694
|
|
1,519,670
|
|
499,998
|
|
170,088
|
|
139,192
|
|
2,839,642
|
|
Chief Financial Officer
|
2018
|
511,458
|
|
1,174,164
|
|
374,940
|
|
480,257
|
|
431,233
|
|
2,972,052
|
|
|
2017
|
296,759
|
|
3,158,878
|
|
—
|
|
269,641
|
|
157,907
|
|
3,883,185
|
|
Keyna Skeffington
|
2019
|
424,183
|
|
683,719
|
|
224,988
|
|
106,289
|
|
128,751
|
|
1,567,930
|
|
Senior Vice President, General Counsel and Corporate Secretary
|
2018
|
410,166
|
|
658,627
|
|
162,473
|
|
251,619
|
|
134,393
|
|
1,617,278
|
|
|
2017
|
215,599
|
|
274,962
|
|
258,412
|
|
118,407
|
|
108,865
|
|
976,245
|
|
Edward Andrle
|
2019
|
429,231
|
|
569,913
|
|
187,479
|
|
107,116
|
|
81,202
|
|
1,374,941
|
|
General Manager, NM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Alistair Simpson
|
2019
|
424,183
|
|
569,913
|
|
187,479
|
|
113,445
|
|
153,660
|
|
1,448,680
|
|
General Manager, CS
|
|
|
|
|
|
|
|
(1)
|
For amounts paid in salary and bonus compensation in 2019, we used an exchange rate of $1.275738014 per British Pound, which reflects the applicable period average published rate from our BOPC Accounting System between January 1, 2019 and December 31, 2019. The BOPC Accounting System uses Bloomberg as a source to obtain exchange rates. Salaries for our NEOs are reviewed and, if thought appropriate by the Compensation Committee, increased or decreased with effect on April 1st. The salaries indicated here thus reflect three months of the prior year's base salary and nine months of the new base
|
(2)
|
Amounts reflect the full grant-date fair value of RSUs and SARs granted computed in accordance with Federal Accounting Standards Board Accounting Standards Codification (“FASB ASC”) Topic 718, rather than the amounts paid to or realized by the named individual. We provide information regarding the assumptions used to calculate the value of all RSUs and SARs awards made to executive officers in Note 2 to our audited financial statements in our US Annual Report on Form 10-K for the year ended December 31, 2019. For additional information regarding the RSUs and SARs awards reported herein, see “—
Compensation Discussion and Analysis — 2019 Long-Term Incentive Plan
” and "—
Compensation Discussion and Analysis — 2019 Grants of Plan-Based Awards.
"
|
(3)
|
Values in this column reflect payments in respect of the relevant year's short-term incentive plan.
|
(4)
|
The amounts reported in the All Other Compensation column represent the aggregate dollar amount for all other benefits and payment received by our NEOs. The following table shows the nature of the benefits and payments and specific amounts for each of our NEOs in 2019:
|
|
Severance and Termination Payments
|
Supplemental Health Insurance
|
Housing Allowance
|
Car Allowance
|
Qualified Supplemental Pension Payments
|
Non-Qualified Deferred Compensation and Defined Contribution Plan Registrant Contributions
|
Cash in Lieu of Pension
|
Other
|
Total
|
|||||||||
($)
|
($)
|
($) (a)
|
($)(b)
|
($) (c)
|
($) (d)
|
($) (e)
|
($) (f)
|
($)
|
||||||||||
Damien McDonald
|
—
|
|
28,381
|
|
122,471
|
|
22,644
|
|
—
|
|
—
|
|
162,643
|
|
26,087
|
|
362,226
|
|
Thad Huston
|
—
|
|
21,823
|
|
—
|
|
16,840
|
|
—
|
|
—
|
|
89,360
|
|
11,169
|
|
139,192
|
|
Keyna Skeffington
|
—
|
|
34,628
|
|
—
|
|
16,840
|
|
—
|
|
—
|
|
69,922
|
|
7,361
|
|
128,751
|
|
Edward Andrle
|
—
|
|
26,215
|
|
—
|
|
—
|
|
11,200
|
|
40,222
|
|
—
|
|
3,565
|
|
81,202
|
|
Alistair Simpson
|
—
|
|
28,259
|
|
—
|
|
16,840
|
|
—
|
|
—
|
|
70,865
|
|
37,696
|
|
153,660
|
|
(a)
|
Represents the housing allowance to Mr. McDonald under the terms of his service agreement.
|
(b)
|
Represents the car allowance for each of Messrs. McDonald, Huston, Alistair and Ms. Skeffington. These benefits and allowances are customary in UK executive compensation packages.
|
(c)
|
Represents Company contributions on behalf of our NEOs to tax-qualified defined contribution plans. (
see - 2019 Pension Benefits
)
|
(d)
|
Represents Company contributions to a partially non-qualified defined contribution plan equal to the amount of company contributions made on behalf of the executive officer on top of the maximum amounts that may be tax-qualified under the supplemental pension plan. (
see - 2019 Nonqualified Deferred Compensation
)
|
(e)
|
Represents cash received in lieu of pension (
see - 2019 Pension Benefits
). In respect of Mr. McDonald: the Company contributed £20,000 ($25,215) into a personal pension plan administered by Aegon, and a further £127,490 ($162,643) was paid as cash in lieu of pension. Mr. McDonald's service agreement entitles him to a pension contribution equal to 15% of the aggregate of his base salary and bonus. As cash in lieu entails a UK employers' national insurance charge in the amount of 13.8% of the cash in lieu, the cash paid is decreased by this amount in order that the payment by the Company remains relatively cost-neutral. In respect of Mr. Huston, the Company contributed £70,046 ($89,360) as cash in lieu of pension. Mr. Huston's service agreement entitles him to a pension contribution equal to 15% of the aggregate of his base salary and bonus. As in the case of Mr. McDonald's cash in lieu, the cash paid is decreased by 13.8%. In respect of Ms. Skeffington, the Company contributed £54,809 ($69,922). Ms. Skeffington's service contract contains the same provision as Mr. Huston's and her cash in lieu is thus similarly reduced to reflect UK employers' national insurance contributions payable by the Company. In respect of Mr. Simpson, the Company contributed £55,548 ($70,865). Mr. Simpson's service contract contains the same provision as Mr. Huston and Ms. Skeffington and his cash in lieu is thus similarly reduced to reflect UK employers' national insurance contribution payable by the Company.
|
(f)
|
For Mr. McDonald, this represents a school tuition fee allowance for Mr. McDonald's children ($26,087). As to Mr. Huston, this represents gym membership ($2,373) and tax assistance ($8,796). As to Ms. Skeffington this represents tax assistance ($7,361). As to Mr. Andrle, this represents group term life insurance ($3,565). As to Mr. Simpson, this represents a school tuition fee allowance for Mr. Simpson's children ($29,770) and tax assistance ($7,926).
|
Name
|
Grant Date
|
Estimated Future Payouts Under Non-Equity Incentive Plan Awards
|
Estimated Future Payouts Under Equity Incentive Plan: Performance Stock Units (PSUs) (#)
|
All Other Stock Awards: Number of Shares of Service-Based RSUs (#)
|
All Other Option Awards: Number of Securities Underlying SARs (#)
|
Exercise or Base Price of SAR Awards ($/Sh)
|
|
Grant Date Fair value of RSU and SAR Awards ($)(1)(2)
|
|||||||||||||||
Threshold ($)
|
Target ($)
|
Maximum ($)
|
Threshold ($)
|
Target ($)
|
Maximum ($)
|
||||||||||||||||||
Damien McDonald
|
|
0
|
|
869,283
|
|
1,486,474
|
|
|
|
|
|
—
|
|
|
|
|
|||||||
|
03/30/2019
|
|
|
|
6,170
|
|
15,424
|
|
30,848
|
|
|
—
|
|
|
(2
|
)
|
1,559,339
|
|
|||||
|
03/30/2019
|
|
|
|
3,085
|
|
15,424
|
|
30,848
|
|
|
|
|
(2
|
)
|
1,499,984
|
|
||||||
|
03/30/2019
|
|
|
|
|
|
|
12,853
|
|
|
|
(1
|
)
|
1,249,954
|
|
||||||||
|
03/30/2019
|
|
|
|
|
|
|
|
39,357
|
|
97.25
|
|
(2
|
)
|
1,249,978
|
|
|||||||
Thad Huston
|
|
0
|
360,339
|
|
576,542
|
|
|
|
|
|
|
|
|
|
|||||||||
|
03/30/2019
|
|
|
|
2,056
|
|
5,141
|
|
10,282
|
|
|
—
|
|
|
(2
|
)
|
519,746
|
|
|||||
|
03/30/2019
|
|
|
|
1,028
|
|
5,141
|
|
10,282
|
|
|
|
|
(2
|
)
|
499,962
|
|
||||||
|
03/30/2019
|
|
|
|
|
|
|
5,141
|
|
|
|
(1
|
)
|
499,962
|
|
||||||||
|
03/30/2019
|
|
|
|
|
|
|
|
15,743
|
|
97.25
|
|
(2
|
)
|
499,998
|
|
|||||||
Keyna Skeffington
|
|
0
|
225,178
|
|
360,285
|
|
|
|
|
|
|
|
|
|
|||||||||
|
03/30/2019
|
|
|
|
925
|
|
2,313
|
|
4,626
|
|
|
—
|
|
|
(2
|
)
|
233,840
|
|
|||||
|
03/30/2019
|
|
|
|
463
|
|
2,313
|
|
4,262
|
|
|
|
|
(2
|
)
|
224,939
|
|
||||||
|
03/30/2019
|
|
|
|
|
|
|
2,313
|
|
|
|
(1
|
)
|
224,939
|
|
||||||||
|
03/30/2019
|
|
|
|
|
|
|
|
7,084
|
|
97.25
|
|
(2
|
)
|
224,988
|
|
|||||||
Edward Andrle
|
|
0
|
274,658
|
|
428,466
|
|
|
|
|
|
|
|
|
|
|||||||||
|
03/30/2019
|
|
|
|
771
|
|
1,928
|
|
3,856
|
|
|
—
|
|
|
(2
|
)
|
194,917
|
|
|||||
|
03/30/2019
|
|
|
|
386
|
|
1,928
|
|
3,856
|
|
|
|
|
(2
|
)
|
187,498
|
|
||||||
|
03/30/2019
|
|
|
|
|
|
|
1,928
|
|
|
|
(1
|
)
|
187,498
|
|
||||||||
|
03/30/2019
|
|
|
|
|
|
|
|
5,903
|
|
97.25
|
|
(2
|
)
|
187,479
|
|
|||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
Alistair Simpson
|
|
0
|
191,918
|
|
299,392
|
|
|
|
|
|
|
|
|
|
|||||||||
|
03/30/2019
|
|
|
|
771
|
|
1,928
|
|
3,856
|
|
|
—
|
|
|
(2
|
)
|
194,917
|
|
|||||
|
03/30/2019
|
|
|
|
386
|
|
1,928
|
|
3,856
|
|
|
|
|
(2
|
)
|
187,498
|
|
||||||
|
03/30/2019
|
|
|
|
|
|
|
1,928
|
|
|
|
(1
|
)
|
187,498
|
|
||||||||
|
03/30/2019
|
|
|
|
|
|
|
|
5,903
|
|
97.25
|
|
(2
|
)
|
187,479
|
|
(1)
|
The amounts reported represent the fair value of the RSU and SARs awards computed in accordance with FASB ASC Topic 718 on the grant date. The fair value for RSU awards is calculated by multiplying the number of units in each award by the closing price of an ordinary share of our stock on Nasdaq on the grant date, eventually discounted in case of a market price condition. The fair value for SARs awards is calculated by multiplying the number of rights subject to the award by the Black-Scholes value of an option for an ordinary share of our stock on the grant date. For a further discussion of the accounting treatment of the RSU and SAR awards, see “Note 2. Basis of Presentation, Use of Accounting Estimates and Significant Accounting Policies” included in the consolidated financial statements accompanying our US Annual Report on Form 10-K for the year ended December 31, 2019.
|
(2)
|
The amounts reported represent the fair value of the PSU awards computed in accordance with FASB ASC Topic 718 on the grant date. LivaNova received a computed Fair Value from an outside source, MTI Consulting, that computed the Fair Value of the LivaNova PLC (LIVN) PSU contracts using the risk-neutral approach (i.e., assuming hedging and selling of the contract).
|
|
Option Awards
|
Stock Awards
|
Name
|
Number of Securities Underlying Unexercised Options (#) Exercisable (1)
|
Number of Securities Underlying Unexercised Options (#) Unexercis-able (2)
|
Option Exercise Price ($)
|
Option Expiration Date
|
Number of Shares or Units of Stock That Have Not Vested (#)(3)
|
Market Value of Shares or Units of Stock That Have Not Vested ($)(4)
|
Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested
|
Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested
|
|||||||||||
Damien McDonald
|
87,114
|
|
43,556
|
|
44.79
|
|
11/4/2026
|
|
|
|
|
|
|||||||
|
10,378
|
|
31,134
|
|
88.38
|
|
3/15/2028
|
|
|
|
|
|
|
|
|
||||
|
—
|
|
39,357
|
|
97.25
|
|
3/30/2029
|
|
|
|
|
|
|
|
|
||||
|
|
|
|
|
|
|
16,744
|
|
(5
|
)
|
1,263,000
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
26,704
|
|
(6
|
)
|
2,014,283
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
8,901
|
|
(7
|
)
|
671,402
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
9,546
|
|
(8
|
)
|
720,055
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
12,853
|
|
(9
|
)
|
969,502
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|
|
|
|
12,729
|
|
(10
|
)
|
960,148
|
|
|||
|
|
|
|
|
|
|
|
|
|
|
12,729
|
|
(11
|
)
|
960,148
|
|
|||
|
|
|
|
|
|
|
|
|
|
|
15,424
|
|
(12
|
)
|
1,163,432
|
|
|||
|
|
|
|
|
|
|
|
|
|
|
15,424
|
|
(13
|
)
|
1,163,432
|
|
|||
Thad Huston
|
3,460
|
|
10,377
|
|
88.38
|
|
3/15/2028
|
|
|
|
|
|
|
|
|
||||
|
—
|
|
15,743
|
|
97.25
|
|
3/30/2029
|
|
|
|
|
|
|
|
|
||||
|
|
|
|
|
|
|
3,189
|
|
(14
|
)
|
240,546
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
9,567
|
|
(15
|
)
|
721,639
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
19,813
|
|
(16
|
)
|
1,494,495
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
3,182
|
|
(8
|
)
|
240,018
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
5,141
|
|
(9
|
)
|
387,786
|
|
|
|
—
|
|
|||
|
|
|
|
|
|
|
|
|
|
|
4,243
|
|
(10
|
)
|
320,049
|
|
|||
|
|
|
|
|
|
|
|
|
|
|
4,243
|
|
(11
|
)
|
320,049
|
|
|||
|
|
|
|
|
|
|
|
|
|
|
5,141
|
|
(12
|
)
|
387,786
|
|
|||
|
|
|
|
|
|
|
|
|
|
|
5,141
|
|
(13
|
)
|
387,786
|
|
|||
Keyna Skeffington
|
7,602
|
|
7,601
|
|
59.97
|
|
6/12/2027
|
|
|
|
|
|
|||||||
|
1,499
|
|
4,497
|
|
88.38
|
|
3/15/2028
|
|
|
|
|
|
|||||||
|
—
|
|
7,084
|
|
97.25
|
|
3/30/2029
|
|
|
|
|
|
|
|
|
||||
|
|
|
|
|
|
|
2,292
|
|
(17
|
)
|
172,886
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
1,378
|
|
(8
|
)
|
103,943
|
|
|
|
|
|
|||
|
|
|
|
|
901
|
|
(18
|
)
|
67,962
|
|
|
|
|
|
|||||
|
|
|
|
|
2,313
|
|
(9
|
)
|
174,470
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
1,838
|
|
(10
|
)
|
138,640
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
1,838
|
|
(11
|
)
|
138,640
|
|
|||
|
|
|
|
|
|
|
|
|
|
|
2,313
|
|
(12
|
)
|
174,470
|
|
|||
|
|
|
|
|
|
|
|
|
|
|
2,313
|
|
(13
|
)
|
174,470
|
|
|||
Edward Andrle
|
29,717
|
|
0
|
|
69.39
|
|
10/19/2020
|
|
|
|
|
|
|
|
|
||||
|
1,724
|
|
5,169
|
|
88.38
|
|
3/15/2028
|
|
|
|
|
|
|
|
|
||||
|
—
|
|
5,903
|
|
97.25
|
|
3/30/2029
|
|
|
|
|
|
|
|
|
||||
|
|
|
|
|
|
|
10,416
|
|
(19
|
)
|
785,679
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
1,375
|
|
(7
|
)
|
103,716
|
|
|
|
|
|
|
|
|
|
|
|
|
4,127
|
|
(6
|
)
|
311,300
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
1,590
|
|
(8
|
)
|
119,934
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
1,928
|
|
(9
|
)
|
145,429
|
|
|
|
—
|
|
|||
|
|
|
|
|
|
|
|
|
|
|
2,121
|
|
(10
|
)
|
159,987
|
|
|||
|
|
|
|
|
|
|
|
|
|
|
2,121
|
|
(11
|
)
|
159,987
|
|
|||
|
|
|
|
|
|
|
|
|
|
|
1,928
|
|
(12
|
)
|
145,429
|
|
|||
|
|
|
|
|
|
|
|
|
|
|
1,928
|
|
(13
|
)
|
145,429
|
|
|||
Alistair Simpson
|
1,724
|
|
5,169
|
|
88.38
|
|
3/15/2028
|
|
|
|
|
|
|
|
|
||||
|
—
|
|
5,903
|
|
97.25
|
|
3/30/2029
|
|
|
|
|
|
|
|
|
||||
|
|
|
|
|
|
|
1,208
|
|
(7
|
)
|
91,119
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
3,624
|
|
(6
|
)
|
273,358
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
1,590
|
|
(8
|
)
|
119,934
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
1,928
|
|
(9
|
)
|
145,429
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|
|
|
|
2,121
|
|
(10
|
)
|
159,987
|
|
|||
|
|
|
|
|
|
|
|
|
|
|
2,121
|
|
(11
|
)
|
159,987
|
|
|||
|
|
|
|
|
|
|
|
|
|
|
1,928
|
|
(12
|
)
|
145,429
|
|
|||
|
|
|
|
|
|
|
|
|
|
|
1,928
|
|
(13
|
)
|
145,429
|
|
(1)
|
This column reflects SARs that are exercisable. The terms of the SARs stipulate that they may be exercised up to three months after a termination and in no event (even with continued employment) after the expiration date.
|
(2)
|
This column reflects SARs that are not yet exercisable as they have not yet vested. The SARs were granted with a vesting schedule over four years (25% per year.)
|
(3)
|
This column reflects RSUs that have not vested. All RSUs vest 25% per year on each of the first four anniversaries of the grant date.
|
(4)
|
Amounts reflect the market value of the outstanding RSUs. Amounts calculated using the closing price of our ordinary shares on December 31, 2019, or $75.43, multiplied by the number of units that have not yet vested.
|
(5)
|
Represents RSUs granted on November 4, 2016.
|
(6)
|
Represents PSUs granted on May 5, 2017. These PSUs had a market factor that was met on March 1, 2018, therefore the remaining shares are now service based. These PSUs vest 25% per year on each anniversary date of March 1, 2018.
|
(7)
|
Represents service based RSUs granted on May 5, 2017.
|
(8)
|
Represents service based RSUs granted on March 15, 2018.
|
(9)
|
Represents service based RSUs granted on March 30, 2019.
|
(10)
|
Represents PSUs granted on March 15, 2018. These PSUs are subject to achievement of a three-year cumulative adjusted free cash flow target (the "FCF Target"). This award has a three-year cliff vesting schedule.
|
(11)
|
Represents PSUs granted on March 15, 2018. These PSUs are subject to a performance or market condition based on a relative total shareholder return (rTSR). This award has a three-year cliff vesting schedule.
|
(12)
|
Represents PSUs granted on March 30, 2019. These PSUs are subject to achievement of a three-year cumulative adjusted free cash flow target (the "FCF Target"). This award has a three-year cliff vesting schedule.
|
(13)
|
Represents PSUs granted on March 30, 2019. These PSUs are subject to a performance or market condition based on a relative total shareholder return (rTSR). This award has a three-year cliff vesting schedule.
|
(14)
|
Represents service based RSUs granted on May 20, 2017.
|
(15)
|
Represents service based RSUs granted on May 20, 2017. These RSUs had a market factor that was met on March 1, 2018, therefore the remaining shares are now service based.
|
(16)
|
Represents service based RSUs granted on May 23, 2017.
|
(17)
|
Represents service based RSUs granted on June 12, 2017.
|
(18)
|
Represents service based RSUs granted on September 15, 2018.
|
(19)
|
Represents service based RSUs granted on March 11, 2016.
|
|
Stock Options
|
Stock Shares
|
||
Name
|
Number of LivaNova Option Shares Acquired on Exercise (#)
|
Value Realized on Exercise ($)
|
Number of LivaNova Shares Acquired on Vesting (#)
|
Value Realized on Vesting ($)
|
Damien McDonald
|
|
|
37,731
|
3,109,651
|
Thad Huston
|
|
|
17,346
|
1,382,921
|
Keyna Skeffington
|
|
|
1,907
|
152,963
|
Edward Andrle
|
29,718
|
156,614
|
9,621
|
902,900
|
Alistair Simpson
|
|
|
2,947
|
270,040
|
Name
|
Executive
Contributions
in
Last Fiscal Year
($)
|
Registrant
Contributions in
Last Fiscal Year
($) (1)
|
Aggregate
Earnings
in Last
Fiscal Year
($)
|
Aggregate
Withdrawals/
Distributions
in
Last Fiscal
Year
($)
|
Aggregate
Balance at
Last
Fiscal Year
($)
|
|||||
Edward Andrle
|
—
|
|
40,222
|
|
30,254
|
|
—
|
|
169,015
|
|
Type of Payment or Benefit
|
Termination without Cause (1)
|
Separation due to Change in Control (2)
|
Separation due to Disability (3)
|
Separation due to Death (4)
|
Separation due to Retirement
|
|||||||||
Severance
|
$
|
933,202
|
|
—
|
|
—
|
|
$
|
3,732,809
|
|
—
|
|
||
STIP
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
||||
LTIP
|
—
|
|
$
|
6,972,797
|
|
$
|
1,334,556
|
|
$
|
1,334,556
|
|
—
|
|
|
Benefits
|
$
|
333,845
|
|
—
|
|
—
|
|
—
|
|
—
|
|
|||
Total
|
$
|
1,267,047
|
|
$
|
6,972,797
|
|
$
|
1,334,556
|
|
$
|
5,067,365
|
|
—
|
|
(1)
|
The potential payment in case of termination without cause represents 12 months of base salary ($933,202) and includes a cash amount representing the value of the following benefits for a period of 12 months: pension ($162,643), accommodation ($122,471), school allowance ($26,086), and car allowance ($22,644). The Company may elect to pay this severance amount in installments, and in this case, if Mr. McDonald secures alternative employment, then the gross installments payable after the date when alternative employment commences will be reduced by a sum equal to the gross amount of his income from the alternative employment. As to pension, this amount reflects 15% of Mr. McDonald's compensation (consisting of base).
|
(2)
|
The potential payment in case of separation due to change in control is calculated adding (i) the amount resulting from multiplying the 74,748 RSUs subject to accelerated vesting by the closing market price at December 31, 2019 ($75.43) and (ii) the amount resulting from multiplying each SARs award subject to accelerated vesting by the difference between the closing market price at December 31, 2019 ($75.43) and the exercise price for each SAR, as follows (43,556 SARs with an exercise price of $44.79). This does not include SARs where the exercise price exceeds the market price.
|
(3)
|
The potential payment amount in case of separation due to disability represents LTIP payments calculated by multiplying each SARs award subject to accelerated vesting in case of a disability by the difference between the closing market price at December 31, 2019 ($75.43) and the exercise price for each SAR, as follows (43,556 SARs with an exercise price of $44.79). This does not include SARs where the exercise price exceeds the market price.
|
(4)
|
The payment amount in case of separation due to death represents four times the base salary as a lump sum (payable by a third party insurer under a policy held by the Company for its employees) tax-free amount to the nominated person(s) plus LTIP potential payments in case of separation due to death calculated by multiplying each SARs award subject to accelerated vesting by the difference between the closing market price at December 31, 2019 ($75.43) and the exercise price for each SAR, as follows (43,556 SARs with an exercise price of $44.79).
|
(5)
|
For the amounts on this table, we used an exchange rate of $1.275738014 per British Pound, each of which reflects the applicable period average published rate from our BOPC Accounting System between January 1, 2019 and December 31, 2019.
|
Type of Payment or Benefit
|
Termination Without Cause (1)
|
Separation due to Change in Control (2)
|
Separation due to Disability
|
Separation due to Death (3)
|
Separation due to Retirement
|
||||||||
Severance
|
$
|
516,674
|
|
—
|
|
—
|
|
$
|
2,066,696
|
|
—
|
|
|
STIP
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
|||
LTIP
|
—
|
|
$
|
3,084,484
|
|
—
|
|
—
|
|
—
|
|
||
Benefits
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
|||
Total
|
$
|
516,674
|
|
$
|
3,084,484
|
|
—
|
|
$
|
2,066,696
|
|
—
|
|
(1)
|
The potential payment in case of termination without cause represents 12 months of base salary ($516,674). The Company may elect to pay this severance amount in installments, and in this case, if Mr. Huston secures alternative employment, then the gross installments payable after the date when alternative employment commences will be reduced by a sum equal to the gross amount of his income from the alternative employment.
|
(2)
|
The potential payments in case of separation due to change in control are calculated adding the amount resulting from multiplying the 40,892 RSUs subject to accelerated vesting in case of a change in control by the closing market price at December 31, 2019 ($75.43) The SARs were underwater, therefore not part of this payout calculation).
|
(3)
|
The exercise price of the SARs was higher than the market price and, therefore, not part of this payout calculation.
|
(4)
|
The payment amount in case of separation due to death represents four times the base salary as a lump sum (payable by a third party insurer under a policy held by the Company for its employees) tax-free amount to the nominated person(s).
|
(5)
|
For the amounts on this table, we used an exchange rate of $1.275738014 per British Pound, each of which reflects the applicable period average published rate from our BOPC Accounting System between January 1, 2019 and December 31, 2019.
|
Type of Payment or Benefit
|
Termination without Cause (1)
|
Separation due to Change in Control (2)
|
Separation due to Disability (3)
|
Separation due to Death (4)
|
Separation due to Retirement
|
||||||||
Severance
|
$
|
433,751
|
|
—
|
|
—
|
|
$
|
1,735,004
|
|
—
|
|
|
STIP
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
|||
LTIP (1)
|
—
|
|
$
|
695,535
|
|
—
|
|
$
|
176,275
|
|
—
|
|
|
Benefits
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
|||
Total
|
$
|
433,751
|
|
$
|
695,535
|
|
—
|
|
$
|
1,911,279
|
|
—
|
|
(1)
|
The potential payment in case of termination without cause represents 12 months of base salary ($433,571). We may elect to pay this severance amount in installments, and in this case, if Ms. Skeffington secures alternative employment, then the gross installments payable after the date when alternative employment commences will be reduced by a sum equal to the gross amount of her income from the alternative employment.
|
(2)
|
The potential payment in case of separation due to change in control is calculated by adding (i) the amount resulting from multiplying the 6,884 RSUs subject to accelerated vesting by the closing market price at December 31, 2019 ($75.43) and (ii) the amount resulting multiplying each SARs award subject to accelerated vesting by the difference between the closing market price at December 31, 2019 ($75.43) and the exercise price for each SAR, as follows (11,402 SARs with an exercise price of $59.97). This does not include SARs where the exercise price exceeds the market price.
|
(3)
|
The payment in case of separation due to death represents four times the base salary as a lump sum (payable by a third party insurer under a policy held by the Company for its employees) tax-free amount to the nominated person(s) plus LTIP potential payments calculated by adding the amount resulting from multiplying each SARs award subject to accelerated vesting by the difference between the closing market price at December 31, 2019 ($75.43) and the exercise price for each SAR, as follows (11,402 SARs with an exercise price of $59.97). This does not include SARs where the exercise price exceeds the market price.
|
(5)
|
For the amounts on this table, we used an exchange rate of $1.275738014 per British Pound, each of which reflects the applicable period average published rate from our BOPC Accounting System between January 1, 2019 and December 31, 2019.
|
Type of Payment or Benefit
|
Termination without Cause ($) (1)
|
Separation due to Change in Control (2)
|
Separation due to Disability
|
Separation due to Death (3)
|
Separation due to Retirement
|
||||||||
Severance
|
$
|
440,000
|
|
—
|
|
—
|
|
$
|
500,000
|
|
—
|
|
|
STIP
|
$
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
||
LTIP
|
$
|
—
|
|
$
|
1,466,057
|
|
—
|
|
—
|
|
—
|
|
|
Benefits
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
|||
Total
|
440,000
|
|
$
|
1,466,057
|
|
—
|
|
$
|
500,000
|
|
—
|
|
(1)
|
The potential payment in case of separation due to change in control is calculated by adding (i) the amount resulting from multiplying the 19,436 RSUs subject to accelerated vesting by the closing market price at December 31, 2019 ($75.43). The SARs that were underwater were not part of this payout calculation.
|
(2)
|
The payment in case of separation due to death represents a payment equal to 1.5 times base salary up to a maximum of $500,000 under a Company group life insurance policy.
|
Type of Payment or Benefit
|
Termination without Cause ($)(1)
|
Separation due to Change in Control (2)
|
Separation due to Disability (3)
|
Separation due to Death (4)
|
Separation due to Retirement
|
|||||||||
Severance
|
$
|
433,751
|
|
—
|
|
—
|
|
$
|
1,735,004
|
|
—
|
|
||
STIP
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
||||
LTIP (1)
|
—
|
|
$
|
850,122
|
|
$
|
220,281
|
|
$
|
220,281
|
|
—
|
|
|
Benefits
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
||||
Total
|
$
|
433,751
|
|
$
|
850,122
|
|
$
|
220,281
|
|
$
|
1,955,285
|
|
—
|
|
(1)
|
The potential payment in case of termination without cause represents 12 months of base salary ($433,751). We may elect to pay this severance amount in installments, and in this case, if Mr. Simpson secures alternative employment, then the gross installments payable after the date when alternative employment commences will be reduced by a sum equal to the gross amount of her income from the alternative employment.
|
(2)
|
The potential payment in case of separation due to change in control is calculated by adding (i) the amount resulting from multiplying the 8,350 RSUs subject to accelerated vesting by the closing market price at December 31, 2019 ($75.43) and (ii) the amount resulting multiplying each SARs award subject to accelerated vesting by the difference between the closing market price at December 31, 2019 ($75.43) and the exercise price for each SAR, as follows (7,829 SARs with an exercise price of $56.17 and 4,816 SARs with an exercise price of $61). This does not include SARs where the exercise price exceeds the market price.
|
(3)
|
The potential payment in case of disability is calculated adding the amounts resulting from multiplying each SARs award subject to accelerated vesting by the difference between the closing market price at December 31, 2019 ($75.43) and the exercise price for each SAR, as follows (7,829 SARs with an exercise price of $56.17 and 4,816 SARs with an exercise price of $61). This does not include SARs where the exercise price exceeds the market price.
|
(4)
|
The payment in case of separation due to death represents four times the base salary as a lump sum (payable by a third party insurer under a policy held by the Company for its employees) tax-free amount to the nominated person(s) plus LTIP potential payments calculated by adding the amount resulting from multiplying each SARs award subject to accelerated vesting by the difference between the closing market price at December 31, 2019 ($75.43) and the exercise price for each SAR, as follows (7,829 SARs with an exercise price of $56.17 and 4,816 SARs with an exercise price of $61). This does not include SARs where the exercise price exceeds the market price.
|
(5)
|
For the amounts on this table, we used an exchange rate of $1.275738014 per British Pound, each of which reflects the applicable period average published rate from our BOPC Accounting System between January 1, 2019 and December 31, 2019.
|
1.
|
As of October 1, 2019, our employee population consisted of 4,035 individuals working at our parent company and consolidated subsidiaries, with approximately 32% of these individuals located in the United States, 6% located in Canada, 52% located in Europe
,
and 10% located in various countries in Southeast Asia and South America.
|
◦
|
We selected October 1, 2019 to allow sufficient time to identify the median employee given the global scope of our operations.
|
2.
|
Our employee population, after taking into consideration the adjustments permitted by SEC rules (as described below), consisted of 3,810 individuals.
|
◦
|
Using the
de minimis
exception, we limited our employee population to individuals residing in Europe, North America, Japan and Australia.
|
◦
|
Given
the global distribution of our employee population, we have a variety of pay elements in the compensation arrangements of our
employees.
For example, while most of our employees participate in our short-term incentive plan, the incentive compensation element for some of our employees residing in the US, Japan and Europe is based on commissions. They do not participate in our short-incentive plan. Consequently, we selected base salary or wages plus overtime pay as the most appropriate consistently applied compensation measure to identify the median employee.
|
◦
|
We annualized the compensation of all permanent
employees
who were hired in fiscal 2019 but did not work for
us
or our consolidated subsidiaries for the
entire
fiscal year.
|
◦
|
We did
not make any cost-of-living adjustments in identifying
the median
employee.
|
3.
|
With respect to the annual total compensation of our CEO, we used the amount reported in
the
"Total" column of our 2019 Summary Compensation Table
included
in this proxy statement
. We applied the same approach to determine the annual total compensation of the identified median employee.
|
•
|
annual board retainer fee of $110,000 ($185,000 for the Board Chair)
|
•
|
committee chair fees:
|
◦
|
$15,000 (Nominating and Corporate Governance Committee)
|
◦
|
$20,000 (Compensation Committee)
|
◦
|
$30,000 (Audit and Compliance Committee)
|
•
|
committee member fees (for members other than the committee chairs):
|
◦
|
$6,000 (Nominating and Corporate Governance Committee)
|
◦
|
$8,000 (Compensation Committee)
|
◦
|
$15,000 (Audit and Compliance Committee)
|
Name
|
Fees Earned or Paid in Cash ($)
|
Stock Awards ($)(1)
|
Total ($)
|
|||
Francesco Bianchi
|
133,000
|
|
109,890
|
|
242,890
|
|
William Kozy
|
116,000
|
|
109,890
|
|
225,890
|
|
Daniel Moore
|
185,000
|
|
184,908
|
|
369,908
|
|
Hugh Morrison
|
146,000
|
|
109,890
|
|
255,890
|
|
Alfred Novak
|
133,000
|
|
109,890
|
|
242,890
|
|
Sharon O’Kane
|
125,000
|
|
109,890
|
|
234,890
|
|
Arthur Rosenthal
|
130,000
|
|
109,890
|
|
239,890
|
|
Andrea Saia
|
125,000
|
|
109,890
|
|
234,890
|
|
Stacy Enxing Seng (2)
|
62,890
|
|
109,890
|
|
172,780
|
|
(1)
|
Amounts reflect the full grant-date fair value of RSUs granted in 2019 computed in accordance with FASB ASC Topic 718, rather than the amounts paid to or realized by the named individual. We provide information regarding the assumptions used to calculate the value of all stock awards and option awards made to our directors in “Note 2. Basis of Presentation, Use of Accounting Estimates and Significant Accounting Policies in the Company's US Annual Report on Form 10-K for the year ended December 31, 2019. The RSUs shown in the table will vest on the earlier of (i) June 18, 2020 and (ii) the date of a Change in Control. As of December 31, 2019, all RSU awards were unvested. The stock award values shown above correspond to the following number of RSUs: for Mr. Moore 2,524 RSUs; and for all other directors listed above, 1,500 RSUs.
|
(2)
|
Ms. Stacy Enxing Seng was elected to the Board at the 2019 AGM and was paid a pro rated cash retainer fee for 2019.
|
•
|
each of our NEOs;
|
•
|
each director;
|
•
|
all current executive officers and directors as a group; and
|
•
|
each person known by us to own beneficially more than 5% of the outstanding ordinary shares.
|
Amount and Nature of Beneficial Ownership (1)
|
|||||||
Name of Beneficial Owner
|
Shares
Owned
|
Shares
Acquirable
Within 60 Days
|
Total Beneficial
Ownership
|
Percent of
Class
(2)
|
|||
Named Executive Officers:
|
|||||||
Damien McDonald
|
43,481
|
|
4,451
|
|
47,932
|
|
*
|
Edward Andrle
|
46,241
|
|
688
|
|
46,929
|
|
*
|
Thad Huston
|
20,910
|
|
11,502
|
|
32,412
|
|
*
|
Alistair Simpson
|
3,440
|
|
604
|
|
4,044
|
|
*
|
Keyna Skeffington
|
2,216
|
|
1,146
|
|
3,362
|
|
*
|
Directors:
|
|||||||
Francesco Bianchi
|
1,520
|
|
—
|
|
1,520
|
|
*
|
Stacy Enxing Seng
|
—
|
|
—
|
|
—
|
|
*
|
William Kozy
|
1,576
|
|
—
|
|
1,576
|
|
*
|
Daniel Moore (3)
|
28,352
|
|
—
|
|
28,352
|
|
*
|
Hugh Morrison (4)
|
1,520
|
|
—
|
|
1,520
|
|
*
|
Alfred Novak
|
9,570
|
|
—
|
|
9,570
|
|
*
|
Sharon O’Kane, Ph.D.
|
4,228
|
|
—
|
|
4,228
|
|
*
|
Arthur Rosenthal, Ph.D.
|
18,615
|
|
—
|
|
18,615
|
|
*
|
Andrea Saia
|
2,998
|
|
—
|
|
2,998
|
|
*
|
All current executive officers
|
184,667
|
|
18,391
|
|
203,058
|
|
*
|
and directors as a group (14
|
|||||||
persons)
|
|||||||
5% Holders: (5)
|
|||||||
BlackRock, Inc. (6)
|
5,954,330
|
|
—
|
|
5,954,330
|
|
12.05%
|
55 East 52nd Street
|
|||||||
New York, NY 10055
|
|||||||
Franklin Resources, Inc. (7)
|
3,348,444
|
|
—
|
|
3,348,444
|
|
6.78%
|
One Franklin Parkway
|
|||||||
San Mateo, CA 94403-1906
|
|||||||
T. Rowe Price Associates, Inc. (8)
|
2,766,521
|
|
—
|
|
2,766,521
|
|
5.60%
|
100 E. Pratt Street
|
|||||||
Baltimore, MD 21202
|
|||||||
Harris Associates L.P. (9)
|
2,697,007
|
|
—
|
|
2,697,007
|
|
5.46%
|
111. S. Wacker, Suite 4000
|
|||||||
Chicago, IL 60606
|
|||||||
PRIMECAP Management Company (10)
|
2,437,830
|
|
—
|
|
2,437,830
|
|
5.02%
|
177 E. Colorado Blvd., 11th Floor
|
|||||||
Pasadena, CA 91105
|
|||||||
(1)
|
Beneficial ownership is determined in accordance with the SEC’s rules and regulations and generally includes voting or investment power with respect to securities. LivaNova ordinary shares subject to options and warrants currently
exercisable, or exercisable within 60 days after April 20, 2020, are deemed outstanding for purposes of computing the percentage of shares beneficially owned by the person holding such rights, but are not deemed outstanding for computing the percentage of
|
(2)
|
Based on total shares outstanding of 48,578,778 as of April 20, 2020.
|
(3)
|
The Total Beneficial Ownership column excludes 2,586 shares owned by the DJM Family Partnership, Ltd., in which Mr. Moore’s spouse, Grace M. Moore, owns a limited partner interest and holds sole investment power. Mr. Moore disclaims beneficial ownership over such shares.
|
(4)
|
1,520 shares owned by Mr. Morrison are pledged as collateral in connection with a margin account.
|
(5)
|
5% holders are as of April 28, 2020, as reported on Schedules 13G filed with the SEC.
|
(6)
|
The shares set forth in the table reflect the number of shares beneficially owned as of December 31, 2019, based on a Schedule 13G/A filed on February 4, 2020 by BlackRock, Inc. In such Schedule 13G/A, BlackRock, Inc. reported having sole voting power over 5,859,623 shares, shared voting power over no shares, sole dispositive power over 5,954,330 shares and shared dispositive power over no shares.
|
(7)
|
The shares set forth in the table reflect the number of shares beneficially owned as December 31, 2019, based on a Schedule 13G filed on February 5, 2020 by Franklin Resources, Inc. and its affiliates. In such Schedule 13G, Franklin Resources, Inc. and its affiliates reported having sole voting power over 2,419,644 shares, shared voting power over 38,000 shares, sole dispositive power over 3,310,444 shares and shared dispositive power over 38,000 shares.
|
(8)
|
The shares set forth in the table reflect the number of shares beneficially owned as December 31, 2019, based on a Schedule 13G filed on February 14, 2020 by T. Rowe Price Associates, Inc. In such Schedule 13G, T. Rowe Price Associates, Inc. reported having sole voting power over 828,934 shares, shared voting power over no shares, sole dispositive power over 2,766,521 shares and shared dispositive power over no shares.
|
(9)
|
The shares set forth in the table reflect the number of shares beneficially owned as December 31, 2019, based on a Schedule 13G filed on February 14, 2020 by Harris Associates L.P. In such Schedule 13G, Harris Associates L.P. reported having sole voting power over 1,845,813 shares, shared voting power over no shares, sole dispositive power over 2,697,007 shares and shared dispositive power over no shares.
|
(10)
|
The shares set forth in the table reflect the number of shares beneficially owned as March 31, 2020, based on a Schedule 13G filed on April 24, 2020 by PRIMECAP Management Company. In such Schedule 13G, PRIMECAP Management Company reported having sole voting power over 2,437,830 shares, shared voting power over no shares, sole dispositive power over 2,437,830 shares and shared dispositive power over no shares.
|
Plan category
|
Number of
securities
to be issued upon exercise of outstanding options, warrants and rights (#) |
Weighted-average
exercise price of outstanding
options,
warrants and rights ($) |
Number of
securities
remaining available for future issuance under equity compensation plans (#) |
||||||
Equity compensation plans approved by security holders
|
|||||||||
LivaNova PLC 2015 Incentive Award Plan and Sub-Plan(1)
|
2,788,448
|
|
77.06
|
|
4,903,894
|
|
|||
Cyberonics Legacy Plans(2)
|
235,844
|
|
52.10
|
|
1,855,720
|
|
|||
Equity compensation plans not approved by security holders
|
|||||||||
Cyberonics, Inc. New Employee Equity Inducement Plan(4)
|
290,185
|
|
|||||||
Total
|
3,024,292
|
|
64.58
|
|
7,049,799
|
|
(1)
|
The LivaNova 2015 Incentive Award Plan and the Sub-Plan were approved by our Board and our sole shareholder, effective on October 16, 2015. Amounts represent the number of LivaNova Shares issuable upon the exercise or settlement
|
(2)
|
The Cyberonics, Inc. Amended and Restated 1996 Stock Option Plan (“1996 Stock Plan”), the Cyberonics, Inc. Amended and Restated 1997 Stock Plan (“1997 Stock Plan”), the Cyberonics, Inc. 2005 Stock Plan (“2005 Stock Plan”) and the Cyberonics, Inc. 2009 Stock Plan (“2009 Stock Plan”) were approved by Cyberonics board and became effective in November 1996, November 2000, March 2005 and August 2009, respectively. Options granted under the 1996 Stock Plan (now expired), the 1997 Stock Plan (no longer available) and the 2005 Stock Plan (no longer available) generally vest ratably over four or five years following their date of grant. Option awards have a maximum term of 10 years from grant date. In connection with the merger of Sorin and Cyberonics, on October 19, 2015, we assumed the 1996 Stock Plan, 1997 Stock Plan, 2005 Stock Plan and the 2009 Stock Plan and all outstanding Cyberonics stock options granted thereunder (9,375; 102,121; 500; and 689,526, respectively), were fully vested, canceled and converted into an option to purchase one LivaNova Share. The amount represents the number of LivaNova Shares that may be issuable upon exercise of the converted option awards as of December 31, 2019. Based on the unused share reserve of the assumed Cyberonics, Inc. 2009 Stock Plan, there remain 1,855,720 LivaNova Shares available for issuance thereunder, as converted in connection with the above-described merger Transaction.
|
(3)
|
The Cyberonics, Inc. New Employee Equity Inducement Plan (“New Employee Plan”) was not approved by the shareholders of Cyberonics. The New Employee Plan provides for the award of unrestricted shares, restricted stock and stock options to newly hired Cyberonics employees. On October 19, 2015, we assumed the New Employee Plan and each outstanding Cyberonics stock option granted thereunder was fully vested, canceled and converted into an option to purchase one LivaNova Share. The amounts represent the number of LivaNova Shares that may be issuable upon exercise of the converted options and the total number of shares that remain available for issuance under the New Employee Plan as of December 31, 2019.
|
•
|
a senior officer (which shall include, at a minimum, each executive officer/Section 16 officer) or director;
|
•
|
a shareholder owning more than 5% of the Company (or our controlled affiliates);
|
•
|
a person who is an immediate family member of a senior officer or director; and
|
•
|
an entity that is owned or controlled by someone listed above, or an entity in which someone listed above has a substantial ownership interest or control.
|
Directors
|
Nasdaq "Independent Director"
|
Nasdaq Independence for Compensation Committee Purposes
|
"Non-Employee Director"
|
Audit Committee Financial Expert
|
Francesco Bianchi
|
X
|
X
|
X
|
X
|
Stacy Enxing Seng
|
X
|
X
|
X
|
|
William Kozy
|
X
|
X
|
X
|
|
Damien McDonald
|
||||
Daniel Moore
|
X
|
X
|
X
|
|
Hugh Morrison
|
X
|
X
|
X
|
X
|
Alfred Novak
|
X
|
X
|
X
|
X
|
Sharon O'Kane
|
X
|
X
|
X
|
|
Arthur Rosenthal
|
X
|
X
|
X
|
|
Andrea Saia
|
X
|
X
|
X
|
•
|
there were no "disagreements" (as that term is defined in Item 304(a)(1)(iv) of SEC Regulation S-K and the instructions to Item 304) between us and PwC S.p.A. on any matters of accounting principles or practices, financial statement disclosure, or auditing scope or procedures, which disagreements, if not resolved to PwC S.p.A.'s satisfaction would have caused PwC S.p.A. to make reference to the subject matter of the disagreement(s) in connection with this report;
|
•
|
there were no "reportable events" (as that term is defined in Item 304(a)(1)(v) of SEC Regulation S-K); and
|
•
|
neither we nor anyone on our behalf consulted with PwC US regarding (i) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on our consolidated financial statement, and neither a written report was provided to us nor oral advice was provided that PwC USA concluded was an important factor considered by us in reaching a decision as to the accounting, auditing or financial reporting issues, or (ii) any matter that was either the subject of a disagreement (as that term is defined in Item 304(a)(1)(iv) of SEC Regulation S-K and the instructions to Item 304) or a reportable event (as defined in Item 304(a)(1)(v) of SEC Regulation S-K). We provided the disclosure required by Item 304 to PwC S.p.A. The letter received from PwC S.p.A. was filed as Exhibit 16.1 to the Current Report on Form 8-K that we filed with the SEC on March 26, 2018.
|
Year Ended December 31, 2019
|
Year Ended December 31, 2018
|
|||||
(in thousands)
|
||||||
Audit Fees(1)
|
$
|
7,510
|
|
$
|
8,274
|
|
Audit-Related Fees(2)
|
-
|
|
$
|
18
|
|
|
Tax Fees(3)
|
$
|
443
|
|
$
|
387
|
|
All Other Fees(4)
|
1
|
|
$
|
1
|
|
|
Total
|
$
|
7,954
|
|
$
|
8,680
|
|
(1)
|
Audit Fees are fees we paid to PwC for professional services related to the audit of our annual financial statements and the review of our quarterly financial statements, and for services that are normally provided by the firm in connection with US or international statutory and regulatory filings or engagements.
|
(2)
|
Audit-Related Fees consist of aggregate fees to PwC for assurance services, other than those included in Audit Fees, related to the sale of our Cardiac Rhythm Management Business Franchise.
|
(3)
|
Tax Fees include applicable fees paid to PwC for tax services, including tax compliance and tax advice.
|
(4)
|
All Other Fees in 2019 and 2018 are for fees for disclosure checklist access.
|
ITEM 15.
|
EXHIBITS, FINANCIAL STATEMENT SCHEDULES.
|
|
LIVANOVA PLC
|
|
|
|
|
|
By:
|
/s/ DAMIEN MCDONALD
|
|
|
Damien McDonald
|
|
|
Chief Executive Officer
|
|
|
(Principal Executive Officer)
|
|
LIVANOVA PLC
|
|
|
|
|
|
By:
|
/s/ THAD HUSTON
|
|
|
Thad Huston
|
|
|
Chief Financial Officer
|
|
|
(Principal Financial Officer)
|
|
LIVANOVA PLC
|
|
|
|
|
|
By:
|
/s/ DAMIEN MCDONALD
|
|
|
Damien McDonald
|
|
|
Chief Executive Officer
|
|
|
(Principal Executive Officer)
|
|
LIVANOVA PLC
|
|
|
|
|
|
By:
|
/s/ THAD HUSTON
|
|
|
Thad Huston
|
|
|
Chief Financial Officer
|
|
|
(Principal Financial Officer)
|